
    
      This is a Phase 3 multicenter, double-blind, double-dummy, randomized study. Only subjects
      with PV who have received HU for at least 12 weeks, have been receiving a stable dose before
      screening, and still have symptoms related to PV will be enrolled.

      Subjects will be randomized (1:1) to 1 of 2 treatment arms:

      A: ruxolitinib and HU-placebo B: HU and ruxolitinib-placebo

      Subjects randomized to either arm may be eligible to transition to open-label ruxolitinib
      after Week 16.
    
  